Form 4: Acelyrin, Inc. Executive Granted Stock Options

Shephard Mpofu, Chief Medical Officer of Acelyrin, Inc., was granted stock options to purchase 328,860 shares of common stock on May 23, 2024.

Summary

• On May 23, 2024, Shephard Mpofu, the Chief Medical Officer of Acelyrin, Inc., was granted employee stock options.
• These options allow him to purchase 328,860 shares of Acelyrin's common stock at an exercise price of $4.22 per share.
• The options vest over time, with 1/4 vesting on May 9, 2025, and the remainder vesting monthly thereafter, contingent upon continued service.
• The options expire on May 22, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and aligns their interests with the company's success.

Positives

• The granting of stock options to a key executive like the Chief Medical Officer can be seen as an incentive to align their interests with the company's long-term success.

Industry Context

Stock options are a common form of compensation in the biotechnology industry, used to attract and retain talent and align employee incentives with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Acelyrin.
• Comparable companies such as BioNTech, Moderna, and Regeneron also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view this as a positive incentive for the Chief Medical Officer to drive company success.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates